Investors Purchase Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 23,660 call options on the company. This represents an increase of 33% compared to the average volume of 17,739 call options.

Boston Scientific Price Performance

Shares of BSX traded up $0.28 during trading hours on Tuesday, hitting $74.40. 9,601,702 shares of the stock were exchanged, compared to its average volume of 17,176,426. The stock’s 50-day moving average price is $92.85 and its two-hundred day moving average price is $98.47. Boston Scientific has a 12-month low of $74.00 and a 12-month high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market cap of $110.30 billion, a price-to-earnings ratio of 38.35, a price-to-earnings-growth ratio of 1.60 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Apollon Wealth Management LLC grew its position in Boston Scientific by 8.4% in the second quarter. Apollon Wealth Management LLC now owns 24,826 shares of the medical equipment provider’s stock worth $2,667,000 after acquiring an additional 1,929 shares during the period. CWM LLC raised its position in Boston Scientific by 36.9% in the second quarter. CWM LLC now owns 51,316 shares of the medical equipment provider’s stock valued at $5,512,000 after purchasing an additional 13,840 shares during the period. Welch Group LLC raised its position in Boston Scientific by 3.5% in the second quarter. Welch Group LLC now owns 4,641 shares of the medical equipment provider’s stock valued at $498,000 after purchasing an additional 159 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its stake in shares of Boston Scientific by 6.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 40,748 shares of the medical equipment provider’s stock valued at $4,377,000 after purchasing an additional 2,293 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Barclays decreased their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. TD Cowen lowered their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Needham & Company LLC dropped their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada lowered their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Evercore dropped their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.43.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.